You are here: Home > HCP > ASCI > ASCI Mechanism of Action

Patient website

Website dedicated to help patients, their family and friends about the cancer immunotherapeutic approach in an easy-to-understand format.

Visit Patient website

MAGRIT trial

Website providing information about the now recruiting Non-Small Cell Lung Cancer phase III clinical study

www.ascitrials.com

This section explains the mechanism of action of ASCI:

Upon administration of the ASCI, the recombinant protein is taken up by antigen-presenting cells (APCs) at the injection site.
These cells will migrate to the lymph node and present peptides to CD4+ and CD8+ T-cells, upon combination with MHC class I or II molecules.
This epitope presentation may lead to the activation of these T-cells; activated T-cells will lead to the lysis of the tumor cells in a highly specific manner.

Login

If this is your first time at this site, please click here to register.

For legal reasons, this page is intended solely for healthcare professionals. This is why we ask you to register.

Last update: 27-May-2009

ASCIs are investigational compounds